Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03355144 · ClinicalTrials.gov registry record · NA
Resident Observed Burnout After Daily Supplementation With Coffee
A NA study, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 39
- Enrollment target
NCT03355144: Completed NA study, sponsored by NYU Langone Health.
NCT03355144 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 39 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03355144, a NA study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 39 participants
- Enrollment target
Study Summary
Coffee drinking is frequently reported as a negative outcome in studies on burnout, but the effect of an increased coffee intake on resident burnout has not been reported in the literature. This study is a prospective, interventional cohort study enrolling up to 50 residents from the Internal Medicine Residency Program to look at the relationship between coffee and resident burnout.
Primary Outcome
14 question survey measuring number of cups of coffee and level of exhaustion
Interventions
- DIETARY_SUPPLEMENT Daily Supplementation with Coffee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2018-03-22 |
| Est. Completion | 2018-04-12 |
| Phase | NA |
What the finished NCT03355144 record still lists
NCT03355144 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Daily Supplementation with Coffee is the first listed.
NCT03355144 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03355144 about?
NCT03355144 is a clinical study titled "Resident Observed Burnout After Daily Supplementation With Coffee". Coffee drinking is frequently reported as a negative outcome in studies on burnout, but the effect of an increased coffee intake on resident burnout has not been reported in the literature. This study is a prospective, interventional cohort study enrolling up to 50 residents from the Internal Medici...
What is the current status of trial NCT03355144?
This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 2018-03-22. Estimated completion is 2018-04-12.
What interventions are being tested in trial NCT03355144?
The interventions under investigation include: Daily Supplementation with Coffee (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03355144?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03355144's enrollment target sits among peer trials
39 1536th of 2000 higher than 463 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI